Search
AC Immune SA
ACIUAdd to Watchlist
2.510USD
+0.130+5.46%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
255.45MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of AC Immune SA is 9.50, ranking 4 out of 387 in the Biotechnology & Medical Research industry. The average price target is 8.50, with a high of 12.00 and a low of 7.00.
Analyst Rating
Based on
4
analysts
Strong Buy
Current Rating
8.600
Target Price
+261.34%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
177
Total
6
Median
8
Average
Company name
Ratings
Analysts
AC Immune SA
ACIU
4
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
Vertex Pharmaceuticals Inc
VRTX
34
AbbVie Inc
ABBV
33
1
2
3
...
36
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is AC Immune SA's expected revenue for the next quarter?
AC Immune SA's expected revenue is 12.52M.
What is AC Immune SA's price target?
Analysts forecast that AC Immune SA's price target is USD 8.50, with the highest forecast at USD 12.00 and the lowest forecast at USD 7.00.
How have AC Immune SAACIU's recent earnings per share performed?
The market expectation was USD -0.19, while AC Immune SAACIU's earnings per share (EPS) for the previous quarter was USD -0.18. EPS for the next quarter is expected at USD -0.08.
What is the analyst rating for AC Immune SA?
Based on the ratings of AC Immune SA's stock from 4 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.